Fund Holdings — Propel Bio Management, LLC

Total Portfolio Value:
$86.07M
Total Bought:
$8.30M
Total Sold:
$12.37M
Net Transaction:
-$4.07M
Notable People:
Leen Kawas, James Francis Harding
Securities
▲▼
SharesValue
Q4 2024
▲▼
Q1 2025
▲▼
Change
▲▼
Q4 2024
▲▼
Q1 2025
▲▼
Weight (%)
▲▼
Change
▲▼
Plains GP Holdings, L.P.COMM(PAGP)1,272,3601,272,3600$23.39M$27.18M31.57%+$3.79M
Madrigal Pharmaceuticals, Inc.COMM(MDGL)43,03230,032-13,000$13.28M$9.95M11.56%-$3.33M
Akero Therapeutics IncCOMM343,729228,884-114,845$9.56M$9.27M10.76%-$297.3K
Phathom Pharmaceuticals, Inc.COMM(PHAT)989,9271,134,927+145,000$8.04M$7.12M8.27%-$922.2K
Achieve Life Sciences IncCOMM2,453,0922,453,0920$8.63M$6.55M7.61%-$2.09M
Applied Therapeutics IncCOMM9,615,42011,285,420+1,670,000$8.23M$5.52M6.41%-$2.72M
Avidity Biosciences IncCOMM178,500178,5000$5.19M$5.27M6.12%+$78.5K
Abeona Therapeutics Inc.COMM(ABEO)624,022624,0220$3.48M$2.97M3.45%-$505.5K
TScan Therapeutics, Inc.COMM(TCRX)2,087,1392,087,1390$6.34M$2.88M3.35%-$3.46M
Delcath Systems, Inc.COMM(DCTH)17,000177,600+160,600$204.7K$2.26M2.63%+$2.06M
Syndax Pharmaceuticals, Inc.COMM(SNDX)183,259183,2590$2.42M$2.25M2.62%-$171.3K
Zevra Therapeutics, Inc.COMM(ZVRA)179,874179,8740$1.50M$1.35M1.57%-$152.9K
Milestone Pharmaceuticals Inc.COMM(MIST)01,451,557+1,451,557$0$1.16M1.35%+$1.16M
Maat Pharma SacaCOMM3,151166,423+163,272$25.1K$1.04M1.21%+$1.01M
Compass Therapeutics, Inc.COMM(CMPX)0228,317+228,317$0$433.8K0.50%+$433.8K
Athira Pharma IncCOMM1,492,7921,492,7920$875.8K$425.3K0.49%-$450.5K
Eiger BiopharmaceuticalsCOMM146,381146,3810$765.0K$423.0K0.49%-$342.0K
Chinook TherapeuticsCOMM79,35779,3570$9.8K$38.5K0.04%+$28.8K
Ardelyx IncCOMM950,9470-950,947$4.82M$0—-$4.82M
COMPASS Pathways plcCOMM(CMPS)25,2090-25,209$95.3K$0—-$95.3K
Kura Oncology, Inc.COMM(KURA)130,0000-130,000$1.13M$0—-$1.13M
Kymera Therapeutics, Inc.COMM(KYMR)56,3590-56,359$2.27M$0—-$2.27M
Jasper Therapeutics, Inc.COMM(JSPR)20,0000-20,000$427.6K$0—-$427.6K
Page 1 of 1
Propel Bio Management, LLC — 13F Holdings — Q1 2025 | TickerTrail